Original Article
Free Access
The role of insulin-like growth factor II in the malignant transformation of rat liver oval cells
N Zhang, K Siegel, M Odenthal,
R Becker, F Oesch, H P Dienes,
P Schirmacher,
P Steinberg,
M Odenthal
Institute of Toxicology, University of Mainz, Germany
Search for more papers by this authorH P Dienes
Institute of Toxicology, University of Mainz, Germany
Search for more papers by this authorP Schirmacher
Institute of Toxicology, University of Mainz, Germany
Search for more papers by this authorP Steinberg
Institute of Toxicology, University of Mainz, Germany
Search for more papers by this authorN Zhang, K Siegel, M Odenthal,
R Becker, F Oesch, H P Dienes,
P Schirmacher,
P Steinberg,
M Odenthal
Institute of Toxicology, University of Mainz, Germany
Search for more papers by this authorH P Dienes
Institute of Toxicology, University of Mainz, Germany
Search for more papers by this authorP Schirmacher
Institute of Toxicology, University of Mainz, Germany
Search for more papers by this authorP Steinberg
Institute of Toxicology, University of Mainz, Germany
Search for more papers by this authorAbstract
Oval cells are small nonparenchymal epithelial cells that first appear in the periportal areas of the liver and thereafter invade the whole parenchyma when mice or rats are exposed to a variety of chemical carcinogens. In the present study we have analyzed the expression of insulin-like growth factor II (IGF II) in the recently established oval cell line OC/CDE 22 and its malignantly transformed counterpart (the M22 cells) and the biological consequences of the constitutive expression of IGF II in oval cells. OC/CDE 22 cells do not express the above-mentioned growth factor, whereas the M22 cells do and addition of a neutralizing anti-IGF II antibody to M22 cells resulted in an almost complete proliferation stop. The presence of type 1 as well as type 2 insulin-like growth factor receptors in OC/CDE 22 and M22 cells was revealed by Northern blotting; however, only neutralizing antibodies directed against the type 1 IGF receptor were able to inhibit the proliferation of the cultured oval cells. Finally, transfection of an IGF II complementary DNA (cDNA) into OC/CDE 22 cells resulted in the release of active IGF II into the extracellular medium but not in the concomitant malignant transformation of the cells. Taken together these results show that: (1) upon transformation oval cells start producing IGF II and (2) IGF II acts on oval cells as a pure mitogen (without being per se oncogenic) via an autocrine loop involving the activation of the type 1 IGF receptor.
References
- 1 LeRoith D (ed). Insulin-Like Growth Factors:Molecular and Cellular Aspects. Boca Raton: CRC Press, 1991.
- 2 Rotwein P. Structure, evolution, expression and regulation of insulin-like growth factors I and II. Growth Factors 1991; 5: 3–18.
- 3 Roth RA. Structure of the receptor for insulin-like growth factor II: the puzzle amplified. Science 1988; 239: 1269–1271.
- 4 Czech MP. Signal transmission by the insulin-like growth factors. Cell 1989; 59: 235–238.
- 5 Neely EK, Beukers MW, Oh Y, Cohen P, Rosenfeld RG. Insulin-like growth factor receptors. Acta Paediatr Scand 1991; 372 (suppl): 116–123.
- 6 Nissley P, Kiess W, Sklar MM. The IGF-II/mannose-6-phosphate receptor. In: D LeRoith, ed. Insulin-Like Growth Factors: Molecular and Cellular Aspects. Boca Raton: CRC Press, 1991: 111–150.
- 7 Moxham C, Jacobs S. Insulin-like growth factor receptors. In: PN Schofield, ed. The Insulin-Like Growth Factors: Structure and Biological Functions. Oxford: Oxford University Press, 1992: 80–110.
- 8 Kornfeld S. Structure and function of the M6P/IGF-II receptors. Annu Rev Biochem 1992; 61: 307–330.
- 9 Morgan DO, Jarnagin K, Roth RA. Purification and characterization of the receptor for insulin-like growth factor I. Biochemistry 1986; 25: 5560–5564.
- 10 Ullrich A, Gray A, Tarn AW, Yang-Feng T, Tsubokawa M, Collins C, Henzel W, et al. Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity. EMBO J 1986; 5: 2503–2512.
- 11 Morgan DO, Edman JC, Standring DR, Fried VA, Smith MC, Roth RA, Rutter WJ. Insulin-like growth factor II receptor as a multifunctional binding protein. Nature 1987; 329: 301–307.
- 12 Soares MB, Ishii DN, Efstriatiadis A. Developmental and tissue-specific expression of a family of transcripts related to rat insulin-like growth factor II mRNA. Nucleic Acids Res 1985; 14: 1129–1134.
- 13 Gray A, Tarn AW, Dull TJ, Hayflick J, Pintar J, Cavenee WK, Koufos A, et al. Tissue-specific and developmentally regulated transcription of the insulin-like growth factor II gene. DNA 1987; 6: 283–295.
- 14 DeChiara TM, Robertson EJ, Efstriatiadis A. Parental imprinting of the mouse insulin-like growth factor II gene. Cell 1991; 64: 849–859.
- 15 Giannoukakis N, Deal C, Pacquette J, Goodyer C, Polychronakos C. Parental genomic imprinting of the human IGF2 gene. Nat Genet 1993; 4: 98–101.
- 16 Fu XX, Su CY, Lee Y, Hintz R, Biempica L, Snyder R, Rogler CE. Insulin-like growth factor II expression and oval cell proliferation associated with hepatocarcinogenesis in woodchuck hepatitis virus carriers. J Virol 1988; 62: 3422–3430.
- 17 Yang DY, Rogler CE. Analysis of insulin-like growth factor II (IGF II) expression in neoplastic nodules and hepatocellular carcinomas of wood-chucks utilizing “in situ” hybridization and immunocytochemistry. Carcinogenesis 1991; 12: 1893–1901.
- 18 Norstedt G, Levinovitz A, Moller C, Eriksson LC, Andersson G. Expression of insulin-like growth factor I (IGF-I) and IGF-II mRNA during hepatic development, proliferation and carcinogenesis in the rat. Carcinogenesis 1988; 9: 209–213.
- 19 Ueno T, Takahashi K, Matsuguchi T, Ikejiri K, Endo H, Yamamoto M. Reactivation of insulin-like growth factor II gene during hepatocarcinogenesis. Carcinogenesis 1988; 9: 1779–1783.
- 20 Schirmacher P, Held WA, Chisari F, Rustum Y, Wang H-P, Yang D, Rogler CE. Reactivation of insulin-like growth factor II during hepatocarcinogenesis in transgenic mice suggests a role in malignant growth. Cancer Res 1992; 52: 2549–2556.
- 21 Cariani E, Laserre C, Seurin D, Hamelin B, Kemeny F, Franco D, Czech MP, et al. Differential expression of insulin-like growth factor II mRNA in human primary liver cancers, benign liver tumors and liver cirrhosis. Cancer Res 1988; 48: 6844–6849.
- 22 Cariani E, Laserre C, Kemeny F, Franco D, Brechot C. Differential expression of insulin-like growth factor II, a-fetoprotein and hepatitis B virus transcripts in human primary liver cancer. Hepatology 1991; 13: 644–649.
- 23 Derrico A, Grigioni WF, Fiorentino M, Baccarini P, Lamas E, Demitri S, Gozzetti G, et al. Expression of insulin-like growth factor II (IGF II) in human hepatocellular carcinomas: an immunohistochemical study. Pathol Int 1944; 44: 131–137.
- 24 Su Q, Liu YF, Zhang J-F, Zhang S-X, Li D-F, Yang J-J. Expression of insulin-like growth factor II in hepatitis B, cirrhosis and hepatocellular carcinoma: its relationship with hepatitis B virus antigen expression. Hepatology 1994; 19: 788–799.
- 25 Schirmacher P, Rogler CE, Dienes HP. Current pathogenic and molecular concepts in viral liver carcinogenesis. Virchows Arch B Cell Pathol 1993; 63: 71–89.
- 26 Opie EL. The pathogenesis of tumors of the liver produced by butter yellow. J Exp Med 1944; 80: 231–246.
- 27 Farber E. Similarities in the sequence of early histological changes induced in the liver of the rat by ethionine, 2-acetylaminofluorene and 3′-methyl-4-diniethylaminoazobenzene. Cancer Res 1956; 16: 142–148.
- 28 Dempo K, Chisaka N, Yoshida Y, Kaneko A, Onoe T. Immunofluorescent study on alpha-fetoprotein-producing cells in the early stage of 3′-methyl-4-diniethylaminoazobenzene carcinogenesis. Cancer Res 1975; 32: 1282–1287.
- 29 Sell S. Distribution of alpha-fetoprotein and albumin containing cells in the livers of Fischer rats fed four cycles of JV-2-fluorenylacetamide. Cancer Res 1978; 38: 3107–3113.
- 30 Shinozuka H, Lombardi B, Sell S, lammarino RM. Early histological and functional alterations of ethionine liver carcinogen esis in rats fed a choline-devoid diet. Cancer Res 1978; 38: 1092–1098.
- 31 Steinberg P, Hacker HJ, Dienes HP, Oesch F, Bannasch P. Enzyme histochemical and immunohistochemical characterization of oval and parenchy-mal cells proliferating in livers of rats fed a choline-deficient/DL-ethionine-supplemented diet. Carcinogenesis 1991; 12: 225–231.
- 32
Fausto N,
Thompson NL,
Braun L.
Purification and culture of oval cells from rat liver.
In:
IITG Pretlow,
TP Pretlow, eds.
Cell Separation: Methods and Selected Applications.
Orlando:
Academic,
1987:
45–77.
10.1016/B978-0-12-564504-1.50006-4 Google Scholar
- 33 Fausto N. Hepatocyte differentiation and liver progenitor cells. Curr Opin Cell Biol 1990; 2: 1036–1042.
- 34 Evarts RP, Nagy P, Marsden ER, Thorgeirsson SS. A precursor-product relationship exists between oval cells and hepatocytes in rat liver. Carcinogenesis 1987; 8: 1737–1740.
- 35 Evarts RP, Nagy P, Nakatsukasa H, Marsden ER, Thorgeirsson SS. In vivo differentiation of rat liver oval cells into hepatocytes. Cancer Res 1989; 49: 1541–1547.
- 36 Tsao MS, Grisham JW. Hepatocarcinomas, cholangiocarcinomas and hepatoblastomas produced by chemically transformed rat liver epithelial cells. A light- and electron-microscopic analysis. Am J Pathol 1987; 127: 168–181.
- 37 Braun L, Goyette M, Yaswen P, Thompson NL, Fausto N. Growth in culture and tumorigenicity after transfection with the ras oncogene of liver epithelial cells from carcinogen-treated rats. Cancer Res 1987; 47: 4116–4124.
- 38 Braun L, Mikumo R, Fausto N. Production of hepatocellular carcinoma by oval cells: cell cycle expression of c-rnyc andp53 at different stages of oval cell transformation. Cancer Res 1989; 49: 1554–1561.
- 39 Pack R, Heck R, Dienes HP, Oesch F, Steinberg P. Isolation, biochemical characterization, long-term culture, and phenotype modulation of oval cells from carcinogen-fed rats. Exp Cell Res 1993; 204: 198–209.
- 40 Steinberg P, Steinbrecher R, Radaeva S, Schirmacher P, Dienes HP, Oesch F, Bannasch P. Oval cell lines OC/CDE 6 and OC/CDE 22 give rise to cholangiocellular and undifferentiated carcinomas after transformation. Lab Invest 1994; 71: 700–709.
- 41 Hsia CC, Evarts RP, Nakatsukasa H, Marsden ER, Thorgeirsson SS. Occurrence of oval-type cells in hepatitis B virus-associated human hepatocarcinogenesis. Hepatology 1992; 16: 1327–1333.
- 42 Hsia CC, Thorgeirsson SS, Tabor E. Expression of hepatitis B surface and core antigens and transforming growth factor-a in “oval cells” of the liver in patients with hepatocellular carcinoma. J Med Virol 1994; 43: 216–221.
- 43 De Vos R, Desmet V. Ultrastructural characteristics of novel epithelial cell types identified in human pathologic liver specimens with chronic ductular reaction. Am J Pathol 1992; 140: 1441–1451.
- 44 Lee PDK, Hodges D, Hintz RL, Wyche JH, Rosenfeld RG. Identification of receptors for insulin-like growth factor II in two insulin-like growth factor II producing cell lines. Biochem Biophys Res Commun 1986; 134: 595–600.
- 45 Nissley SP, Short PA, Rechler MM, Podskalny JM, Coon HG. Proliferation of Buffalo rat liver cells in serum-free medium does not depend upon multiplication-stimulating activity (MSA). Cell 1977; 11: 441–446.
- 46 Werner H, Woloschak M, Adamo M, Shen-Orr Z, Roberts CT Jr, LeRoith D. Developmental regulation of the rat insulin-like growth factor I receptor gene. Proc Natl Acad Sci U S A 1989; 86: 7451–7455.
- 47 Feinberg AP, Vogelstein B. A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. Anal Biochem 1983; 132: 6–13.
- 48 Chirgwin JM, Przybyla AE, MacDonald RJ, Rutter WJ. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry 1979; 18: 5294–5299.
- 49
J Sambrook,
EF Fritsch,
T Maniatis, eds.
Molecular Cloning: A Laboratory Manual.
Cold Spring Harbor:
Cold Spring Harbor Laboratory,
1989.
10.1111/j.1095-8312.1996.tb01434.x Google Scholar
- 50 Artelt P, Morelle C, Ausmeier M, Fitzek M, Hauser H. Vectors for efficient expression in mammalian fibroblastoid, myeloid and lymphoid cells via transfection or infection. Gene 1988; 68: 213–219.
- 51 Gunning P, Leavitt J, Muscat G, Ng S-Y, Kedes L. A human β-actin expression vector system directs high-level accumulation of antisense transcripts. Proc Natl Acad Sci U S A 1987; 84: 4831–4835.
- 52 Hawkes R, Niday E, Gordon J. A dot-immunobinding assay for monoclonal and other antibodies. Anal Biochem 1982; 119: 1242–147.
- 53 Bennet FC, Yeoman LC. An improved procedure for the “dot-immunobinding” analysis of hybridoma supernatants. J Immunol Meth 1983; 61: 201–207.
- 54 Maurer HR. Towards chemically-defined, serum-free media for mammalian cell culture. In: RI Freshney, ed. Animal Cell Culture: A Practical Approach. Oxford: IRL Press, 1986: 13–31.
- 55 Martin DM, Feldman EL. Regulation of insulin-like growth factor-II expression and its role in autocrine growth of human neuroblastoma cells. J Cell Physiol 1993; 155: 290–300.
- 56 Raile K, Hoflich A, Kessler U, Yang Y, Pfuender M, Blum WF, Kolb H, et al. Human osteosarcoma (U-2 OS) cells express both insulin-like growth factor-I (IGF-I) receptors and insulin-like growth factor-II/mannose-6-phosphate (IGF-II/M6P) receptors and synthesize IGF-II: autocrine growth stimulation by IGF-II via the IGF-I receptor. J Cell Physiol 1994; 159: 531–541.
- 57 Mathieu M, Rochefort H, Barenton B, Prebois C, Vignon F. Interactions of cathepsin-D and insulin-like growth factor-II (IGF-II) on the IGF-II/ mannose-6-phosphate receptor in human breast cancer cells and possible consequences on mitogenic activity of IGF-II. Mol Endocrinology 1990; 4: 1327–1335.
- 58 Thornton WH Jr, Barnett L, MacDonald RS. Insulin-like growth factor-II expression in normal and JV-methyl-JV'-nitro-JV-nitrosoguanidine exposed cell lines: assessment by flow cytometry. In Vitro Cell Dev Biol 1993; 29A: 114–116.
- 59 Zvibel I, Brill S, Reid LM. Insulin-like growth factor II regulation of gene expression in rat and human hepatomas. J Cell Physiol 1995; 162: 36–43.
- 60 Rong S, Bodescot M, Blair D, Dunn J, Nakamura T, Mizuno K, Park M, et al. Tumorigenicity of the met-proto- oncogene and the gene for hepatocyte growth factor. Mol Cell Biol 1992; 12: 5152–5158.
- 61 Kanda H, Tajima H, Lee G-H, Nomura K, Ohtake K, Matsumoto K, Nakamura T, et al. Hepatocyte growth factor transforms immortalized mouse liver epithelial cells. Oncogene 1993; 8: 3047–3053.
- 62 Zapf J, Schoenle E, Froesch ER. Insulin-like growth factors I and II: some biological actions and receptor binding characteristics of two purified constituents of nonsuppressible insulin-like activity of human serum. Eur J Biochem 1978; 87: 285–296.
- 63 Widmer U, Schmid C, Zapf J, Froesch ER. Effects of insulin-like growth factors on chick embryo hepatocytes. Acta Endocrinologica 1985; 108: 237–244.
- 64 Cross M, Dexter TM. Growth factors in development, transformation, and tumorigenesis. Cell 1991; 64: 271–280.
- 65 Williams GT, Smith CA, Spooncer E, Dexter TM, Taylor DR. Haemopoietic colony stimulating factors promote cell survival by suppressing apoptosis. Nature 1990; 343: 76–79.
- 66 Sirica AE, Mathis GA, Sano N, Elmore LW. Isolation, culture and transplantation of intrahepatic biliary epithelial cells and oval cells. Pathobiology 1990; 58: 44–64.
- 67 Aterman K. The stem cells of the liver–a selective review. J Cancer Res Clin Oncol 1992; 118: 87–115.
- 68 Yang L, Faris RA, Hixson DC. Phenotypic heterogeneity within clonogenic ductal cell populations isolated from normal adult rat liver. Proc Soc Exp Biol Med 1993; 204: 280–288.
